|
NL154600B
(nl)
|
1971-02-10 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
|
|
NL154598B
(nl)
|
1970-11-10 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
|
|
NL154599B
(nl)
|
1970-12-28 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
|
|
US3901654A
(en)
|
1971-06-21 |
1975-08-26 |
Biological Developments |
Receptor assays of biologically active compounds employing biologically specific receptors
|
|
US3853987A
(en)
|
1971-09-01 |
1974-12-10 |
W Dreyer |
Immunological reagent and radioimmuno assay
|
|
US3867517A
(en)
|
1971-12-21 |
1975-02-18 |
Abbott Lab |
Direct radioimmunoassay for antigens and their antibodies
|
|
NL171930C
(nl)
|
1972-05-11 |
1983-06-01 |
Akzo Nv |
Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
|
|
US3850578A
(en)
|
1973-03-12 |
1974-11-26 |
H Mcconnell |
Process for assaying for biologically active molecules
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US3935074A
(en)
|
1973-12-17 |
1976-01-27 |
Syva Company |
Antibody steric hindrance immunoassay with two antibodies
|
|
US3996345A
(en)
|
1974-08-12 |
1976-12-07 |
Syva Company |
Fluorescence quenching with immunological pairs in immunoassays
|
|
US4034074A
(en)
|
1974-09-19 |
1977-07-05 |
The Board Of Trustees Of Leland Stanford Junior University |
Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
|
|
US3984533A
(en)
|
1975-11-13 |
1976-10-05 |
General Electric Company |
Electrophoretic method of detecting antigen-antibody reaction
|
|
US4036945A
(en)
|
1976-05-03 |
1977-07-19 |
The Massachusetts General Hospital |
Composition and method for determining the size and location of myocardial infarcts
|
|
US4098876A
(en)
|
1976-10-26 |
1978-07-04 |
Corning Glass Works |
Reverse sandwich immunoassay
|
|
JPS552602A
(en)
|
1978-06-20 |
1980-01-10 |
Yamasa Shoyu Co Ltd |
1-beta-d-arabinofranosylcytosine-5'-phosphoric acid oleyl ester
|
|
US5206018A
(en)
|
1978-11-03 |
1993-04-27 |
Ayerst, Mckenna & Harrison, Inc. |
Use of rapamycin in treatment of tumors
|
|
US4342828A
(en)
|
1979-07-20 |
1982-08-03 |
Morinaga Milk Industry Co., Ltd. |
Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
|
|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US4879219A
(en)
|
1980-09-19 |
1989-11-07 |
General Hospital Corporation |
Immunoassay utilizing monoclonal high affinity IgM antibodies
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5011771A
(en)
|
1984-04-12 |
1991-04-30 |
The General Hospital Corporation |
Multiepitopic immunometric assay
|
|
JPS61227526A
(ja)
|
1984-07-25 |
1986-10-09 |
Chugai Pharmaceut Co Ltd |
新規なコロニー刺激因子
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
ATE65798T1
(de)
|
1985-02-08 |
1991-08-15 |
Chugai Pharmaceutical Co Ltd |
Menschlicher granuloxcyt-koloniestimulierungsfaktor.
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
EP1186663A1
(en)
|
1985-08-23 |
2002-03-13 |
Kirin-Amgen, Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
EP0220520B1
(en)
|
1985-09-30 |
1991-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Human granulocyte colony stimulating factor
|
|
JPH0618778B2
(ja)
|
1985-10-04 |
1994-03-16 |
中外製薬株式会社 |
白血球減少症治療剤
|
|
DE3777845D1
(de)
|
1986-01-22 |
1992-05-07 |
Chugai Pharmaceutical Co Ltd |
Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
|
|
DE3771509D1
(de)
|
1986-01-22 |
1991-08-29 |
Chugai Pharmaceutical Co Ltd |
Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
|
|
DK203187A
(da)
|
1986-04-22 |
1987-10-23 |
Immunex Corp |
Human g-csf proteinekspression
|
|
GR871067B
(en)
|
1986-07-18 |
1987-11-19 |
Chugai Pharmaceutical Co Ltd |
Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
JPH0725689B2
(ja)
|
1986-10-07 |
1995-03-22 |
中外製薬株式会社 |
顆粒球コロニ−刺激因子を含有する徐放性製剤
|
|
DK174044B1
(da)
|
1986-12-23 |
2002-05-06 |
Kyowa Hakko Kogyo Kk |
Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
|
|
JP2618618B2
(ja)
|
1988-03-04 |
1997-06-11 |
協和醗酵工業株式会社 |
抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
|
|
CA1340810C
(en)
|
1988-03-31 |
1999-11-02 |
Motoo Yamasaki |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
|
ATE111921T1
(de)
|
1988-06-03 |
1994-10-15 |
Chugai Pharmaceutical Co Ltd |
Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
|
|
US5202117A
(en)
|
1988-08-24 |
1993-04-13 |
Koichiro Tsuji |
Method of treating thrombi with g-csf
|
|
US5218092A
(en)
|
1988-09-29 |
1993-06-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US5104651A
(en)
|
1988-12-16 |
1992-04-14 |
Amgen Inc. |
Stabilized hydrophobic protein formulations of g-csf
|
|
WO1990006952A1
(fr)
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
IL96477A0
(en)
|
1989-12-01 |
1991-08-16 |
Amgen Inc |
Megakaryocyte production
|
|
GB9107846D0
(en)
|
1990-04-30 |
1991-05-29 |
Ici Plc |
Polypeptides
|
|
EP0459516A1
(en)
|
1990-06-01 |
1991-12-04 |
Kirin-Amgen, Inc. |
Oral dosage form of biologically active proteins
|
|
JP3249147B2
(ja)
|
1990-06-01 |
2002-01-21 |
キリン−アムジエン・インコーポレーテツド |
生理活性蛋白含有経口製剤
|
|
IE912365A1
(en)
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
DK0546073T3
(da)
|
1990-08-29 |
1998-02-02 |
Genpharm Int |
Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5342774A
(en)
|
1991-05-23 |
1994-08-30 |
Ludwig Institute For Cancer Research |
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
|
|
US5541104A
(en)
|
1991-05-23 |
1996-07-30 |
Ludwig Institute For Cancer Research |
Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
|
|
US6235525B1
(en)
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5250732A
(en)
|
1991-07-18 |
1993-10-05 |
Genentech, Inc. |
Ketamine analogues for treatment of thrombocytopenia
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5961974A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
EP0897983B1
(en)
|
1991-10-25 |
2003-05-07 |
Immunex Corporation |
Antibody against CD40-L
|
|
FR2686900B1
(fr)
|
1992-01-31 |
1995-07-21 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
|
|
US5281521A
(en)
|
1992-07-20 |
1994-01-25 |
The Trustees Of The University Of Pennsylvania |
Modified avidin-biotin technique
|
|
US6222012B1
(en)
|
1992-08-31 |
2001-04-24 |
Ludwig Institute For Cancer Research |
Isolated nonapeptides presented by HLA molecules, and uses thereof
|
|
FI950887A0
(fi)
|
1992-08-31 |
1995-02-27 |
Ludwig Inst Cancer Res |
MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
CA2167091A1
(en)
|
1993-07-26 |
1995-02-02 |
Gordon J. Freeman |
B7-2: ctl a4/cd 28 counter receptor
|
|
CN1038841C
(zh)
|
1993-10-14 |
1998-06-24 |
生化学工业株式会社 |
新型多肽以及由其制备的抗人类免疫缺陷病毒制剂
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US6242566B1
(en)
|
1994-02-10 |
2001-06-05 |
Board Of Trustees Of The Leland Stanford Junior University |
Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
|
|
KR100316209B1
(ko)
|
1994-03-01 |
2002-06-26 |
에드워드 에이. 맥더모 2세, 로이드 제이. 오울드 |
Mage유전자발현에의한암상태의결정
|
|
US5492126A
(en)
|
1994-05-02 |
1996-02-20 |
Focal Surgery |
Probe for medical imaging and therapy using ultrasound
|
|
IL113617A
(en)
|
1994-05-06 |
2007-09-20 |
Florence Faure |
Use of LAG-3 antibodies to prepare a therapeutic agent that stimulates the immune system
|
|
DE69622259T2
(de)
|
1995-03-01 |
2003-03-27 |
Immunex Corp., Seattle |
Cd40 bindendes protein zur stimulierung der immunantwort
|
|
ES2185770T3
(es)
|
1995-04-08 |
2003-05-01 |
Lg Chemical Ltd |
Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6207157B1
(en)
|
1996-04-23 |
2001-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Conjugate vaccine for nontypeable Haemophilus influenzae
|
|
PL188749B1
(pl)
|
1996-10-11 |
2005-04-29 |
Bristol Myers Squibb Co |
Zastosowanie przeciwciała anty-4-1BB i kompozycjaleku
|
|
JP2000516101A
(ja)
|
1996-11-28 |
2000-12-05 |
アンスティテュ ギュスタブ ルシ |
Ｌａｇ−３タンパク質の変異体、その発現及び使用
|
|
WO1998042752A1
(en)
|
1997-03-21 |
1998-10-01 |
Brigham And Women's Hospital Inc. |
Immunotherapeutic ctla-4 binding peptides
|
|
JP2001517957A
(ja)
|
1997-05-14 |
2001-10-09 |
アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド |
ペプチド副甲状腺ホルモン類縁体
|
|
CA2288964A1
(en)
|
1997-05-21 |
1998-11-26 |
Genentech, Inc. |
Novel administration of thrombopoietin
|
|
AU8053598A
(en)
|
1997-05-23 |
1998-12-11 |
Transurgical, Inc. |
Mri-guided therapeutic unit and methods
|
|
US6774279B2
(en)
|
1997-05-30 |
2004-08-10 |
Carnegie Institution Of Washington |
Use of FLP recombinase in mice
|
|
EP0893507A1
(en)
|
1997-07-25 |
1999-01-27 |
Institut Gustave Roussy |
Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
|
|
US6291430B1
(en)
|
1997-09-12 |
2001-09-18 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
|
US6569418B1
(en)
|
1997-12-11 |
2003-05-27 |
University Of Maryland Biotechnology Institute |
Immuno-modulating effects of chemokines in DNA vaccination
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
CA2245224A1
(en)
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Chemokine receptor antagonists and chemotherapeutics
|
|
CA2305787A1
(en)
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
|
AU762472B2
(en)
|
1998-03-13 |
2003-06-26 |
University Of British Columbia, The |
Therapeutic chemokine receptor antagonists
|
|
WO2000009152A1
(en)
|
1998-08-14 |
2000-02-24 |
The University Of British Columbia |
Therapeutic chemokine receptor antagonists
|
|
WO2000006086A2
(en)
|
1998-07-31 |
2000-02-10 |
The Trustees Of Columbia University In The City Of New York |
Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
|
|
US6294459B1
(en)
|
1998-09-03 |
2001-09-25 |
Micron Technology, Inc. |
Anti-reflective coatings and methods for forming and using same
|
|
JP2002526419A
(ja)
|
1998-10-05 |
2002-08-20 |
ファーメクサ エイ／エス |
治療上のワクチン注射のための新規な方法
|
|
WO2000024468A1
(de)
|
1998-10-27 |
2000-05-04 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Verfahren und vorrichtung zur regelung einer gezielten wärmedeponierung in ein material
|
|
US20060079492A1
(en)
|
1999-10-25 |
2006-04-13 |
Ahlem Clarence N |
Compositions and treatment methods
|
|
SI1141028T1
(sl)
|
1998-12-23 |
2010-05-31 |
Pfizer |
Človeška monoklonska protitelesa proti CTLA
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
|
KR20020000554A
(ko)
|
1999-03-29 |
2002-01-05 |
윌슨, 로엔스 알. |
백혈병 치료방법
|
|
WO2000066764A1
(en)
|
1999-05-03 |
2000-11-09 |
Ludwig Institute For Cancer Research |
Methods for increasing t cell proliferation
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
DK1210428T3
(en)
|
1999-08-23 |
2015-06-15 |
Dana Farber Cancer Inst Inc |
PD-1, a receptor for B7-4 AND USE THEREOF
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
JP4093757B2
(ja)
|
1999-08-24 |
2008-06-04 |
メダレックス， インコーポレイテッド |
ヒトｃｔｌａ−４抗体およびその使用
|
|
AU6934600A
(en)
|
1999-08-27 |
2001-03-26 |
Board Of Regents, The University Of Texas System |
Cd40 ligand and cd40 agonist compositions and methods of use
|
|
MXPA02005199A
(es)
|
1999-11-24 |
2002-11-07 |
Schering Corp |
Metodos para inhibir metastasis.
|
|
GB9927757D0
(en)
|
1999-11-25 |
2000-01-26 |
Kennedy Rheumatology Inst |
Treatment of autoimmune diseases
|
|
EP3225632B1
(en)
|
1999-11-30 |
2020-05-06 |
Mayo Foundation for Medical Education and Research |
Antibodies binding to b7-h1, a novel immunoregulatory molecule
|
|
US7034121B2
(en)
|
2000-01-27 |
2006-04-25 |
Genetics Institue, Llc |
Antibodies against CTLA4
|
|
US7172759B2
(en)
|
2000-02-01 |
2007-02-06 |
Pangenetics Bv |
Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies
|
|
WO2001064716A1
(fr)
|
2000-03-03 |
2001-09-07 |
Nobutaka Fujii |
Composes antiviraux
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
DE60103052T2
(de)
|
2000-05-09 |
2005-03-03 |
The University Of British Columbia, Vancouver |
Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
AU2001273096B8
(en)
|
2000-06-28 |
2005-10-13 |
Dana-Farber Cancer Institute, Inc. |
PD-L2 molecules: novel PD-1 ligands and uses therefor
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
ATE465170T1
(de)
|
2000-09-05 |
2010-05-15 |
Biokine Therapeutics Ltd |
Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten
|
|
US8435939B2
(en)
|
2000-09-05 |
2013-05-07 |
Biokine Therapeutics Ltd. |
Polypeptide anti-HIV agent containing the same
|
|
US20020107363A1
(en)
|
2000-09-20 |
2002-08-08 |
Amgen, Inc. |
B7-Like molecules and uses thereof
|
|
US6469543B1
(en)
|
2000-11-09 |
2002-10-22 |
Honeywell International Inc. |
High speed output buffers using voltage followers
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US7630750B2
(en)
|
2001-02-05 |
2009-12-08 |
The Research Foundation For The State University Of New York |
Computer aided treatment planning
|
|
JP3374917B2
(ja)
|
2001-02-16 |
2003-02-10 |
サンケン電気株式会社 |
スイッチング電源装置
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
EP2388590A1
(en)
|
2001-04-02 |
2011-11-23 |
Dana Farber Cancer Institute |
PD-1, a receptor for B7-4, and uses thereof
|
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
|
US8709412B2
(en)
|
2001-06-29 |
2014-04-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of TIM receptor activity in combination with cytoreductive therapy
|
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
|
EP1295895B1
(en)
|
2001-09-19 |
2011-08-10 |
Institut Gustave Roussy |
Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
EP1456652A4
(en)
|
2001-11-13 |
2005-11-02 |
Dana Farber Cancer Inst Inc |
IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
|
|
US20030221931A1
(en)
|
2002-02-28 |
2003-12-04 |
Steve Marsh |
Sliding device
|
|
US20030232410A1
(en)
|
2002-03-21 |
2003-12-18 |
Monika Liljedahl |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
US8774913B2
(en)
|
2002-04-08 |
2014-07-08 |
Medtronic Ardian Luxembourg S.A.R.L. |
Methods and apparatus for intravasculary-induced neuromodulation
|
|
US20030223989A1
(en)
|
2002-04-18 |
2003-12-04 |
Pluenneke John D. |
CD137 agonists to treat patients with IgE-mediated conditions
|
|
EP2243493A1
(en)
|
2002-07-03 |
2010-10-27 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiative composition
|
|
US6887673B2
(en)
|
2002-07-30 |
2005-05-03 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1BB
|
|
ES2403932T3
(es)
|
2002-08-27 |
2013-05-22 |
Biokine Therapeutics Ltd. |
Antagonista de CXCR4 y uso del mismo
|
|
JP4781621B2
(ja)
*
|
2002-08-27 |
2011-09-28 |
バイオカイン セラピューティックス リミテッド |
Ｃｘｃｒ４拮抗薬およびその用途
|
|
DE10240064A1
(de)
|
2002-08-30 |
2004-03-11 |
Universitätsklinikum Freiburg |
CXCR4-Rezeptor-Antagonisten
|
|
US9447434B2
(en)
|
2002-09-05 |
2016-09-20 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
|
MXPA05004022A
(es)
|
2002-10-17 |
2005-10-05 |
Genmab As |
Anticuerpos monoclonales humanos contra cd20.
|
|
JP4666256B2
(ja)
|
2002-12-10 |
2011-04-06 |
小野薬品工業株式会社 |
含窒素複素環化合物およびその医薬用途
|
|
US20050002939A1
(en)
|
2002-12-23 |
2005-01-06 |
Albert Zlotnik |
Tumor killing/tumor regression using CXCR4 antagonists
|
|
JP2006514024A
(ja)
|
2002-12-23 |
2006-04-27 |
イネイト・ファーマ |
Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法
|
|
BR0316880A
(pt)
|
2002-12-23 |
2005-10-25 |
Wyeth Corp |
Anticorpos contra pd-1 e usos dos mesmos
|
|
JP2006524242A
(ja)
*
|
2003-03-27 |
2006-10-26 |
エモリー ユニバーシティー |
Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
|
|
WO2004093871A1
(en)
|
2003-03-27 |
2004-11-04 |
Lankenau Institute For Medical Research |
Novel methods for the treatment of cancer
|
|
US7291631B2
(en)
|
2003-04-11 |
2007-11-06 |
Genzyme Corporation |
CXCR4 chemokine receptor binding compounds
|
|
US8012136B2
(en)
|
2003-05-20 |
2011-09-06 |
Optimyst Systems, Inc. |
Ophthalmic fluid delivery device and method of operation
|
|
CA2525717A1
(en)
|
2003-05-23 |
2004-12-09 |
Wyeth |
Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
AU2004253770C1
(en)
|
2003-07-02 |
2010-04-15 |
Innate Pharma |
PAN-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy
|
|
US20050048054A1
(en)
|
2003-07-11 |
2005-03-03 |
Shino Hanabuchi |
Lymphocytes; methods
|
|
EP2292264A3
(en)
|
2003-07-24 |
2012-12-19 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
|
|
JP2008500013A
(ja)
|
2003-10-03 |
2008-01-10 |
ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド |
Ｔｉｍ−３ポリペプチド
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
CA2542662A1
(en)
|
2003-10-17 |
2005-04-28 |
Novo Nordisk A/S |
Pharmaceutical combinations comprising il-21
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
WO2005079766A2
(en)
|
2004-02-20 |
2005-09-01 |
Novo Nordisk A/S |
Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
|
|
CN1838965B
(zh)
|
2004-03-19 |
2011-07-06 |
森永乳业株式会社 |
用于癌症治疗的药品
|
|
JP2008502597A
(ja)
|
2004-04-30 |
2008-01-31 |
イネイト・ファーマ |
Ｎｋ型ｌｄｇｌのような免疫増殖性障害を処置するための組成物および方法
|
|
AU2005259221B2
(en)
|
2004-07-01 |
2011-02-10 |
Innate Pharma |
Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
|
|
US20060287229A1
(en)
|
2004-07-01 |
2006-12-21 |
Dani Eshel |
Novel CD40 variants
|
|
US7799776B2
(en)
|
2004-07-13 |
2010-09-21 |
The University Of British Columbia |
Indoleamine 2,3-dioxygenase (IDO) inhibitors
|
|
US20060014264A1
(en)
|
2004-07-13 |
2006-01-19 |
Stowers Institute For Medical Research |
Cre/lox system with lox sites having an extended spacer region
|
|
CN101094684A
(zh)
|
2004-08-13 |
2007-12-26 |
阿诺麦德股份有限公司 |
用趋化因子的组合活化祖细胞/干细胞
|
|
JP5525689B2
(ja)
|
2004-11-02 |
2014-06-18 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
過剰増殖性障害を処置するための組成物および方法
|
|
CN104829720B
(zh)
|
2005-01-06 |
2019-01-01 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
JP5855326B2
(ja)
|
2005-01-06 |
2016-02-09 |
ノヴォ ノルディスク アー／エス |
抗ｋｉｒ組み合わせ治療および方法
|
|
US20080233053A1
(en)
|
2005-02-07 |
2008-09-25 |
Pharmalight Inc. |
Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
|
|
WO2006088447A1
(en)
|
2005-02-15 |
2006-08-24 |
Gtc Biotherapeutics, Inc. |
An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
|
|
EP1850872A4
(en)
|
2005-02-15 |
2008-10-15 |
Gtc Biotherapeutics Inc |
METHOD FOR USE OF ANTI-CD-137 ANTIBODY AS RADIOIMMUN THERAPY OR RADIO IMMUNE DETECTION MEANS
|
|
ES2432091T5
(es)
|
2005-03-25 |
2022-03-18 |
Gitr Inc |
Moléculas de unión GITR y usos de las mismas
|
|
LT2650020T
(lt)
|
2005-05-06 |
2016-12-12 |
Providence Health & Services - Oregon |
Trimerinio ox40-immunoglobulino sulietas baltymas ir naudojimo būdai
|
|
CA2970873C
(en)
|
2005-05-09 |
2022-05-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
EP2559690B1
(en)
|
2005-05-10 |
2016-03-30 |
Incyte Holdings Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
|
WO2006126188A2
(en)
|
2005-05-25 |
2006-11-30 |
Hadasit Medical Research Services And Development Ltd. |
Cxcr4 antagonists for wound healing and re-epithelialization
|
|
WO2006133561A1
(en)
|
2005-06-15 |
2006-12-21 |
London Health Sciences Centre Research Inc. |
Method of cancer treatment using sirna silencing
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
CA2619828A1
(en)
|
2005-08-19 |
2007-02-22 |
Genzyme Corporation |
Methods to enhance chemotherapy
|
|
CA2622629A1
(en)
|
2005-09-15 |
2007-03-29 |
Duke University |
Aptamers as agonists
|
|
US7705022B2
(en)
|
2005-10-27 |
2010-04-27 |
Lankenau Institute For Medical Research |
IDO inhibitors and methods of use thereof
|
|
US20090220466A1
(en)
|
2005-12-08 |
2009-09-03 |
Mariusz Ratajczak |
Very small embryonic-like (vsel) stem cells and methods of isolating and using the same
|
|
TWI382974B
(zh)
|
2005-12-20 |
2013-01-21 |
英塞特公司 |
作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物
|
|
WO2007120368A2
(en)
|
2006-01-09 |
2007-10-25 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
|
EP2889309B1
(en)
|
2006-03-03 |
2017-12-27 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of pd-1 or pd-l1
|
|
US20080038231A1
(en)
|
2006-06-15 |
2008-02-14 |
Rodgerson Denis O |
Processing procedure for peripheral blood stem cells
|
|
EP2068868A2
(en)
|
2006-08-02 |
2009-06-17 |
Genzyme Corporation |
Combination therapy
|
|
US7968098B2
(en)
|
2006-08-04 |
2011-06-28 |
Kurume University |
HLA-A24-binding KIF-derived peptide
|
|
US20090074711A1
(en)
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
AU2007319806A1
(en)
|
2006-11-15 |
2008-05-22 |
The Brigham And Women's Hospital, Inc. |
Therapeutic uses of TIM-3 modulators
|
|
GB0624308D0
(en)
|
2006-12-05 |
2007-01-17 |
Molmed Spa |
Combination product
|
|
EP2104507A4
(en)
|
2006-12-21 |
2011-05-25 |
Biokine Therapeutics Ltd |
T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR CANCER THERAPY
|
|
CN105037549B
(zh)
|
2007-01-11 |
2018-09-28 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
|
US8389568B2
(en)
|
2007-03-16 |
2013-03-05 |
Lankenau Institute For Medical Research |
IDO inhibitors and methods of use thereof
|
|
EP2068925A4
(en)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
|
|
SI2170959T1
(sl)
|
2007-06-18 |
2014-04-30 |
Merck Sharp & Dohme B.V. |
Protitelesa proti receptorjem pd-1 za humano programirano smrt
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
GB0722274D0
(en)
|
2007-11-13 |
2007-12-27 |
Ludwig Inst Cancer Res |
New therapeutic method
|
|
EP2227233B1
(en)
|
2007-11-30 |
2013-02-13 |
Newlink Genetics |
Ido inhibitors
|
|
EP2067402A1
(en)
|
2007-12-07 |
2009-06-10 |
Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; |
Transponson-mediated mutagenesis in spermatogonial stem cells
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2009126804A2
(en)
|
2008-04-11 |
2009-10-15 |
The Regents Of The University Of Colorado, A Body Corporate |
Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
|
|
CN102083429B
(zh)
|
2008-04-24 |
2014-05-28 |
新联基因公司 |
Ido抑制剂
|
|
US9931386B2
(en)
|
2008-06-16 |
2018-04-03 |
Atsuo Ochi |
Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
|
|
DK2315756T5
(en)
|
2008-07-08 |
2015-08-03 |
Incyte Corp |
1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase
|
|
WO2010012506A1
(en)
|
2008-07-31 |
2010-02-04 |
Bionorica Research Gmbh |
Cannabinoids for use in treating or preventing cognitive impairment and dementia
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EA201170375A1
(ru)
|
2008-08-25 |
2012-03-30 |
Эмплиммьюн, Инк. |
Антагонисты pd-1 и способы их применения
|
|
WO2010027423A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
|
CA2735421A1
(en)
|
2008-08-29 |
2010-03-04 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Delivery of a cd40 agonist to a tumor draining lymph node of a subject
|
|
CN102149820B
(zh)
|
2008-09-12 |
2014-07-23 |
国立大学法人三重大学 |
能够表达外源gitr配体的细胞
|
|
BRPI0919377A2
(pt)
|
2008-09-26 |
2016-09-27 |
Dana Farber Cancer Inst Inc |
anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
|
|
WO2010063011A2
(en)
|
2008-11-28 |
2010-06-03 |
Emory University |
Methods for the treatment of infections and tumors
|
|
FI4209510T3
(fi)
|
2008-12-09 |
2024-03-22 |
Hoffmann La Roche |
Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
|
|
ES2629337T3
(es)
|
2009-02-09 |
2017-08-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
|
|
ES2609333T3
(es)
|
2009-03-13 |
2017-04-19 |
The Trustees of The University of Pennsylvania-Center for Technology Transfer |
Proteínas de fusión OX40/TRAIL
|
|
ES2681529T3
(es)
|
2009-03-23 |
2018-09-13 |
Ambit Biosciences Corporation |
Métodos de tratamiento utilizando terapia de combinación
|
|
EP2417984B1
(en)
|
2009-04-10 |
2016-03-30 |
Kyowa Hakko Kirin Co., Ltd. |
Method for treatment of blood tumor using anti-tim-3 antibody
|
|
EP2243833A1
(en)
|
2009-04-22 |
2010-10-27 |
Erasmus University Medical Center Rotterdam |
Method for the treatment of acute myeloid leukemia
|
|
WO2010146578A2
(en)
|
2009-06-14 |
2010-12-23 |
Biokine Therapeutics Ltd. |
Peptide therapy for increasing platelet levels
|
|
BRPI1009716A2
(pt)
|
2009-06-15 |
2016-10-11 |
Biokine Therapeutics Ltd |
ligações péptidicas de quemoquina, capazes de inibir o curso da autoimunidade, inflamação e câncer
|
|
RU2595409C2
(ru)
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Анти-gitr-антитела
|
|
US8709417B2
(en)
|
2009-09-30 |
2014-04-29 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
WO2011069121A1
(en)
|
2009-12-04 |
2011-06-09 |
Neostem, Inc. |
Mesenchymal stem cells (mscs) isolated from mobilized peripheral blood
|
|
KR101773216B1
(ko)
|
2009-12-29 |
2017-08-31 |
교와 핫꼬 기린 가부시키가이샤 |
항 ｃｄ27 항체
|
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
|
US20130142815A1
(en)
|
2010-02-09 |
2013-06-06 |
Georiga Health Sciences Univ. Research Inst., Inc. |
Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
|
|
CA2791383C
(en)
|
2010-03-05 |
2022-09-20 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
EP2571512B1
(en)
|
2010-05-17 |
2017-08-23 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
|
PL2581113T3
(pl)
|
2010-06-11 |
2018-11-30 |
Kyowa Hakko Kirin Co., Ltd. |
Przeciwciało anty-tim-3
|
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CA2804550C
(en)
|
2010-07-09 |
2021-01-05 |
Bionovion Holding B.V. |
Agonistic antibody to cd27
|
|
PH12013500395B1
(en)
|
2010-09-09 |
2020-10-16 |
Pfizer |
4-1bb binding molecules
|
|
US20120082687A1
(en)
|
2010-10-04 |
2012-04-05 |
Alex Wah Hin Yeung |
Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
|
|
US20130303460A1
(en)
|
2011-01-10 |
2013-11-14 |
Biokine Therapeutics Ltd. |
Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
|
|
JP2014506576A
(ja)
|
2011-02-10 |
2014-03-17 |
ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド |
４−１ｂｂｌを含むアジュバント組成物
|
|
SG193428A1
(en)
|
2011-03-31 |
2013-10-30 |
Inst Nat Sante Rech Med |
Antibodies directed against icos and uses thereof
|
|
NO2694640T3
(enExample)
|
2011-04-15 |
2018-03-17 |
|
|
|
AU2012249454B2
(en)
|
2011-04-29 |
2016-03-24 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
EA036545B1
(ru)
|
2011-05-25 |
2020-11-20 |
Иннейт Фарма, С.А. |
Анти-kir антитела для лечения воспалительных заболеваний
|
|
US20140234320A1
(en)
|
2011-06-20 |
2014-08-21 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
TW202114735A
(zh)
|
2011-08-01 |
2021-04-16 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
ES2705001T3
(es)
|
2011-11-09 |
2019-03-21 |
Bristol Myers Squibb Co |
Tratamiento de neoplasias hematológicas con un anticuerpo anti-CXCR4
|
|
CN103170757A
(zh)
*
|
2011-12-23 |
2013-06-26 |
富泰华工业（深圳）有限公司 |
锡膏及其制备方法
|
|
EP2819703A4
(en)
|
2012-02-29 |
2015-11-18 |
Benitec Biopharma Ltd |
PAIN TREATMENT
|
|
EP2822957A1
(en)
|
2012-03-07 |
2015-01-14 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
EP2841084B1
(en)
|
2012-04-24 |
2018-05-30 |
Biokine Therapeutics Ltd. |
Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
CA2889182A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
JP6693745B2
(ja)
|
2012-10-30 |
2020-05-13 |
アペクシジェン， インコーポレイテッド |
抗ｃｄ４０抗体および使用方法
|
|
US20140147411A1
(en)
|
2012-11-14 |
2014-05-29 |
U.S. GOVERNMENT represented by the UNITED STATES DEPARTMENT OF VETERANS AFFAIRS |
Methods of treating cancer and testing mutation zygosity related thereto
|
|
CA2891412A1
(en)
|
2012-11-20 |
2014-05-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
|
|
MX379044B
(es)
|
2012-11-27 |
2025-03-10 |
Childrens Medical Center |
Direccion de elementos reguladores distales de bcl11a para reinduccion de hemoglobina fetal.
|
|
DK2925350T3
(da)
|
2012-12-03 |
2019-05-13 |
Bristol Myers Squibb Co |
Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
|
|
EP2928491B1
(en)
|
2012-12-05 |
2018-11-21 |
TheVax Genetics Vaccine Co., Ltd. |
Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
MX2015008697A
(es)
|
2013-01-08 |
2016-08-04 |
Benitec Biopharma Ltd |
Tratamiento contra la degeneración macular relacionada con la edad.
|
|
EP2951209A4
(en)
|
2013-01-31 |
2016-06-22 |
Univ Jefferson |
CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
|
|
ME02917B
(me)
|
2013-03-14 |
2018-10-20 |
Bristol Myers Squibb Co |
Kombinacija dr5 agoniste i anti-pd--1 antagoniste i načini primjene
|
|
WO2014158811A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Newcastle disease viruses and uses thereof
|
|
US10344088B2
(en)
|
2013-03-15 |
2019-07-09 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
ES2675022T3
(es)
|
2013-03-15 |
2018-07-05 |
Bristol-Myers Squibb Company |
Inhibidores de indolamina 2,3-dioxigenasa (IDO)
|
|
PE20151594A1
(es)
|
2013-03-15 |
2015-11-19 |
Bristol Myers Squibb Co |
Inhibidores de indolamina 2-3 dioxigenasa
|
|
EP2970909A4
(en)
|
2013-03-15 |
2017-02-15 |
The University of Chicago |
Methods and compositions related to t-cell activity
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
ES2643321T3
(es)
|
2013-03-24 |
2017-11-22 |
Biokine Therapeutics Ltd. |
Una combinación de un antagonista de CXCR4 y citarabina para su uso en el tratamiento de la leucemia mieloide
|
|
BR112016001420A2
(pt)
|
2013-08-02 |
2018-01-23 |
Aduro Biotech Holdings Europe B V |
combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
|
|
EP3030322A2
(en)
|
2013-08-05 |
2016-06-15 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
WO2015063768A1
(en)
|
2013-10-31 |
2015-05-07 |
Biokine Therapeutics Ltd. |
Methods of treating acute myeloid leukemia with a flt3 mutation
|
|
EP3065772B1
(en)
|
2013-11-05 |
2024-07-24 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
WO2016185475A1
(en)
|
2015-05-20 |
2016-11-24 |
Biokine Therapeutics Ltd. |
Methods of mesenchymal stem cell mobilization and expansion
|
|
CN107921087A
(zh)
*
|
2015-07-16 |
2018-04-17 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
KR102033920B1
(ko)
|
2016-02-23 |
2019-10-18 |
바이오라인알엑스 리미티드 |
급성 골수성 백혈병을 치료하는 방법
|
|
EP3866812A1
(en)
|
2018-10-17 |
2021-08-25 |
BioLineRx Ltd. |
Treatment of metastatic pancreatic adenocarcinoma
|